The Journal of Allergy and Clinical Immunology
Volume 122, Issue 2 , Pages 251-253 , August 2008

Long-acting β-agonists and exercise

  • Miles Weinberger, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Miles Weinberger, MD, Pediatric Department, UIHC, 200 Hawkins Dr, Iowa City, IA 52242.

Received 26 March 2008 ,Revised 14 May 2008 ,Accepted 19 May 2008.

References 

  1. Solis-Cohen S. The use of adrenal substance in the treatment of asthma. JAMA. 1900;34:1164
  2. LaForce C, Alexander M, Deckelmann R, Fabbri LM, Aisanov Z, Cameron R, et al. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy. 2008;63:103–111
  3. Greening AP, Ind P, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid (Allen & Hanburys Limited UK Study Group). Lancet. 1994;344:219–224
  4. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroid. Am J Respir Crit Care Med. 1996;153:1481–1488
  5. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky Pm, SMART Study Group . The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26
  6. Aaronson DW. The “black box” warning and allergy drugs. J Allergy Clin Immunol. 2006;117:40–44
  7. Abu-Hasan M, Tannous B, Weinberger M. Exercise-induced dyspnea in children and adolescents: if not asthma then what?. Ann Allergy Asthma Immunol. 2005;94:366–371
  8. Shapiro GS, Yegen Ü, Xiang J, Kottakis J, Cioppa GD. A randomized, double-blind, single dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol. Clin Ther. 2002;24:2077–2087
  9. Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER. Effect of long-term salmeterol treatment on exercise-induced asthma. N Eng J Med. 1998;339:141–146
  10. Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics. 1997;99:655–659
  11. Anderson SD, Brannon JD. Long-acting β2-adrenoceptor agonists and exercise-induced asthma: lessons to guide us in the future. Pediatr Drugs. 2004;6:161–175
  12. Taylor DR. β-adrenergic receptor polymorphisms: relationship to the β-agonist controversy and clinical implications. Expert Opin Pharmacother. 2007;8:3195–3203
  13. Taylor DR, Hall IP. ADRB2 polymorphisms and β2 agonists. Lancet. 2007;370:2075–2076
  14. Weinberger M, Abu-Hasan M. Life threatening asthma during treatment with salmeterol. N Engl J Med. 2006;335:852–853
  15. Kindermann W. Do inhaled β2 agonists have an ergogenic potential in non-asthmatic competitive athletes?. Sports Med. 2007;37:95–102

 Disclosure of potential conflict of interest: The author has declared that he has no conflict of interest.

PII: S0091-6749(08)01000-2

doi: 10.1016/j.jaci.2008.05.030

The Journal of Allergy and Clinical Immunology
Volume 122, Issue 2 , Pages 251-253 , August 2008

Article Tools

* Image Usage & Resolution